News

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

New data reveals lifileucel shows promising efficacy and safety in treating advanced non-small cell lung cancer, paving the way for potential FDA approval.

Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in patients with advanced ER+, HER2– breast cancer.

Bexmarilimab combined with azacitidine shows promising efficacy and safety in patients with high-risk myelodysplastic syndrome, paving the way for new treatment options.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

Sevabertinib demonstrates promising safety and efficacy in treating non-small cell lung cancer with HER2 or EGFR mutations, offering hope for patients.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.

New research reveals that CD26+ leukemia stem cell levels at diagnosis predict treatment response in chronic myeloid leukemia patients, enhancing TKI therapy strategies.

A recent study highlights disparities in cancer clinical trials among low- and middle-income countries, emphasizing the need for enhanced research initiatives.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.

Novel approaches in MDS focus on HMA doublets, but transplant remains the only curative option to date.

A novel combination therapy shows promising results for advanced esophageal squamous cell carcinoma, achieving high response rates and manageable safety.

Research reveals matched unrelated donor transplants significantly enhance survival rates in leukemia patients compared with haploidentical transplants, despite donor availability.

New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.

XmAb819 shows promising antitumor activity and safety in advanced clear cell renal cell carcinoma, paving the way for future clinical advancements.

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

October 2025 marked a pivotal month in oncology with multiple FDA approvals and designations, enhancing treatment options for various cancers.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

VS-7375 shows promising safety and antitumor activity in advanced solid tumors with KRAS G12D mutation, paving the way for further clinical evaluation.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

A phase 1 trial shows IO-202 combined with azacitidine effectively treats relapsed/refractory monocytic leukemias, demonstrating promising response rates.

A new trial shows that the combination of belzutifan and lenvatinib improves progression-free survival in advanced renal cell carcinoma patients.